X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lexicon lead product Inpefa (sotagliflozin), SGLT2/SGLT1 inhibitor. Currently, it is being evaluated in the Phase III clinical trial studies with patients for the treatment of Diabetes Mellitus Type 1 and chronic kidney failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Endocrinology Product Name: Inpefa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
Lexicon currently intends to use the net proceeds to fund the continued research, development and commercialization of its drug programs, including LX9211, an orally-delivered small molecule compound being developed as a treatment for diabetic peripheral neuropathic pain.
Lead Product(s): LX9211
Therapeutic Area: Neurology Product Name: LX9211
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 11, 2024
Details:
Inpefa (sotagliflozin) is a small molecule dual inhibitor of SGLT1 and SGLT2, which is being evaluated for the treatment of type 1 diabetes and chronic kidney disease.
Lead Product(s): Sotagliflozin
Therapeutic Area: Endocrinology Product Name: Inpefa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
LX9211 is an AAK-1 Inhibitor small molecule drug taken orally as a tablet, it is being investigated for the treatment for diabetic peripheral neuropathic pain.
Lead Product(s): LX9211
Therapeutic Area: Neurology Product Name: LX9211
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
LX9211 is a potent, orally delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1), which is investigated for the treatment of diabetic peripheral neuropathic pain.
Lead Product(s): LX9211
Therapeutic Area: Neurology Product Name: LX9211
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
INPEFA (sotagliflozin) is an oral Tablet inhibitor of two proteins responsible for glucose regulation known as SGLT2 and SGLT1 and reduce the risk of cardiovascular death, hospitalization for heart failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
Lexicon intends to use the proceeds from the public offering to fund the commercial launch of FDA approved, Inpefa (sotagliflozin), an orally-delivered small molecule, a sodium-glucose cotransporter type 2 inhibitor that also inhibits SGLT1, for the treatment of heart failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Citigroup
Deal Size: $71.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 05, 2023
Details:
Lexicon intends to use the proceeds to fund the commercial launch of Inpefa (sotagliflozin), an inhibitor of SGLT2 and SGLT1 approved for the treatment of heart failure, and to fund the continued research and development of its drug candidates.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Citigroup
Deal Size: $62.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 01, 2023
Details:
Lexicon currently intends to use the net proceeds to fund the commercial launch of Inpefa (sotagliflozin), an inhibitor of SGLT2 and SGLT1, recently approved by FDA for the treatment of heart failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Citigroup
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering May 31, 2023
Details:
INPEFA™ (sotagliflozin) is an oral Tablet inhibitor of two proteins responsible for glucose regulation known as SGLT2 and SGLT1 and reduce the risk of cardiovascular death, hospitalization for heart failure.
Lead Product(s): Sotagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inpefa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
